Canagliflozin vs Ertugliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Canagliflozin · Invokana

Marketed by Johnson & Johnson and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT01032629 · Phase 3 · completed

The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.

Next expected readout: December 2026 · NCT05427084 (registry estimate)

Reported efficacy

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline (Day 1) and Week 26); Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)): Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). (met)

Result source: NCT03170518

Ertugliflozin · Steglatro

Marketed by Merck & Co. and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT01986881 · Phase 3 · completed

This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.

Next expected readout: January 2028 · NCT07621380 (registry estimate)

Reported efficacy

Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years); Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) (Baseline and Week 18): Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years (met)

Result source: NCT01986881

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCanagliflozinErtugliflozin
HbA1c, change-0.4% vs 0.4%−0.8 vs placebo100/300 mg · wk 26 · n 84NCT03170518
41 other results
  • -0.7% vs -0.0% 300 mg · wk 26 · n 229 · Phase 3 · primary NCT01106651
  • -0.4% vs -0.0% 300 mg · wk 26 · n 89 · Phase 3 · primary NCT01064414
  • -1.0% vs -0.3% 300 mg · wk 26 · n 112 · Phase 3 · primary NCT01106690
  • -1.1% vs -0.1% 300 mg · wk 26 · n 152 · Phase 3 · primary NCT01106625
  • -1.0% vs 0.1% 300 mg · wk 26 · n 194 · Phase 3 · primary NCT01081834
  • -1.1% vs -0.5% 300 mg · wk 18 · n 227 · Phase 3 · primary NCT01381900
  • -0.6% vs -0.0% 100 mg · wk 26 · n 239 · Phase 3 · primary NCT01106651
  • -0.3% vs -0.0% 100 mg · wk 26 · n 88 · Phase 3 · primary NCT01064414
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 26 · n 155 · Phase 3 · primary NCT01106625
  • -0.8% vs 0.1% 100 mg · wk 26 · n 191 · Phase 3 · primary NCT01081834
  • -1.0% vs -0.5% 100 mg · wk 18 · n 223 · Phase 3 · primary NCT01381900
  • -1.0% vs -0.1% wk 24 · n 70 · Phase 3 · primary NCT02354235
  • -0.9% vs -0.8% 300 mg · wk 52 · n 474 · Phase 3 · primary NCT00968812
  • -1.0% vs -0.7% 300 mg · wk 52 · n 374 · Phase 3 · primary NCT01137812
  • -1.4% vs -1.3% 300 mg · wk 26 · n 234 · Phase 3 · primary NCT01809327
  • -0.9% vs -0.8% 300 mg · wk 26 · n 360 · Phase 3 · primary NCT01106677
  • -0.8% vs -0.8% 100 mg · wk 52 · n 478 · Phase 3 · primary NCT00968812
  • -1.4% vs -1.3% 100 mg · wk 26 · n 230 · Phase 3 · primary NCT01809327
  • -0.8% vs -0.8% 100 mg · wk 26 · n 365 · Phase 3 · primary NCT01106677
  • -1.8% vs -1.3% wk 26 · n 236 · Phase 3 · primary NCT01809327
  • -1.8% vs -1.3% wk 26 · n 235 · Phase 3 · primary NCT01809327
  • -0.3% vs 0.0% 300 mg · wk 338 · n 1352 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.0% 100 mg · wk 338 · n 1392 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.7% 100/300 mg · wk 52 · n 84 · Phase 3 · secondary NCT03170518
  • -0.6% vs 0.1% 100/300 mg · wk 12 · n 84 · Phase 3 · secondary NCT03170518
  • -0.7% vs -0.6% 300 mg · wk 104 · n 474 · Phase 3 · secondary NCT00968812
  • -0.9% vs -0.7% 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 100 mg · wk 104 · n 478 · Phase 3 · secondary NCT00968812
  • -0.7% vs -0.7% 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -0.9% vs -0.2% 300 mg daily · wk 12 · n 60 · Phase 2 · primary NCT00642278
  • -0.8% vs -0.2% 100 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.2% 300 mg twice daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.7% vs -0.2% 200 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.6% vs -0.0% 150 mg Bid · wk 18 · n 91 · Phase 2 · primary NCT01340664
  • -0.5% vs -0.0% 50 mg Bid · wk 18 · n 90 · Phase 2 · primary NCT01340664
  • -0.8% vs -0.2% 50 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.0% wk 26 · n 99 · Phase 4 · primary NCT02025907
  • -1.0% vs 0.1% wk 16 · n 76 · Phase 4 · primary NCT02220920
  • -0.9% vs -1.1% n 76 · Phase 4 · secondary NCT02622113
  • 7.8% vs 8.3% wk 16 · n 15 · Phase 4 · secondary NCT02964585
-1.0% vs 0.2%−1.2 vs placebo15 mg · wk 26 · n 151NCT01958671
65 other results
  • -0.9% vs -0.0% 15 mg · wk 26 · n 205 · Phase 3 · primary NCT02033889
  • -0.9% vs -0.1% 15 mg · wk 26 · n 153 · Phase 3 · primary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 155 · Phase 3 · primary NCT01986855
  • -0.9% vs -0.2% 15 mg · wk 26 · n 169 · Phase 3 · primary NCT02630706
  • -0.8% vs -0.2% 15 mg · wk 18 · n 370 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.2% 5 mg · wk 18 · n 348 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.6% 15 mg · wk 18 · n 54 · Phase 3 · primary NCT01986881
  • -1.0% vs -0.2% 15 mg · wk 18 · n 113 · Phase 3 · primary NCT01986881
  • -0.8% vs 0.2% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT01958671
  • -0.7% vs -0.0% 5 mg · wk 26 · n 207 · Phase 3 · primary NCT02033889
  • -0.8% vs -0.1% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 158 · Phase 3 · primary NCT01986855
  • -1% vs -0.2% 5 mg · wk 26 · n 170 · Phase 3 · primary NCT02630706
  • -0.9% vs -0.6% 5 mg · wk 18 · n 55 · Phase 3 · primary NCT01986881
  • -0.9% vs -0.2% 5 mg · wk 18 · n 100 · Phase 3 · primary NCT01986881
  • -1.7% vs -0.4% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · primary NCT02226003
  • -1.6% vs -0.4% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · primary NCT02226003
  • -0.6% vs 0.1% wk 24 · n 111 · Phase 3 · primary NCT04029480
  • -0.6% vs -0.7% 15 mg · wk 52 · n 440 · Phase 3 · primary NCT01999218
  • -1.1% vs -1.1% 15 mg · wk 26 · n 248 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 5 mg · wk 52 · n 448 · Phase 3 · primary NCT01999218
  • -1.0% vs -1.1% 5 mg · wk 26 · n 250 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · primary NCT02099110
  • -0.5% vs -0.1% 15 mg · wk 104 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 52 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 15 mg · wk 156 · n 1574 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 15 mg · wk 208 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 5 mg · wk 156 · n 1590 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.3% vs -0.1% 15 mg · wk 260 · n 527 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.7% 5 mg · wk 52 · n 179 · Phase 3 · secondary NCT02033889
  • -0.3% vs -0.1% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -0.9% vs -0.6% 15 mg · wk 104 · n 142 · Phase 3 · secondary NCT02033889
  • -1.0% vs -0.7% 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -0.6% vs -0.6% 5 mg · wk 104 · n 147 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -0.5% vs 0.3% 5 mg · wk 24 · n 85 · Phase 3 · secondary NCT04029480
  • -0.2% vs 0.8% wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -0.4% vs 0.3% wk 24 · n 89 · Phase 3 · secondary NCT04029480
  • -0.1% vs 0.2% 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.3% vs 0.2% 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -0.8% vs -0.1% 5 mg · wk 12 · n 53 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 12 · n 50 · Phase 2 · primary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 12 · n 51 · Phase 2 · primary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -0.3% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.1% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT01059825
Body weight, change (kg)-2.9 vs -0.8−2.1 vs placebo300 mg daily · wk 12 · n 62NCT00642278
8 other results
  • -1.5 vs 0.1 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -2.3 vs -0.8 100 mg daily · wk 12 · n 64 · Phase 2 · secondary NCT00642278
  • -1.0 vs 0.1 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -2.9 vs -0.8 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -2.3 vs -0.8 200 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -2.0 vs -0.8 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -3.5 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
  • -6 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
-3.8 vs -1.3−2.5 vs placebo15 mg · wk 208 · n 2746NCT01986881
43 other results
  • -3.4 vs -1.0 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • -3.2 vs -0.7 15 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.4 15 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.3 vs -0.4 15 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.3 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.0 5 mg · wk 156 · n 1595 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.7 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.5 vs -0.4 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.4 5 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -4.6 vs -1.2 15 mg · wk 260 · n 530 · Phase 3 · secondary NCT01986881
  • -3.6 vs -0.2 15 mg · wk 104 · n 145 · Phase 3 · secondary NCT02033889
  • -3.4 vs 0.1 15 mg · wk 52 · n 178 · Phase 3 · secondary NCT02033889
  • -2.8 vs -0.9 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -2.9 vs -1.3 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -2.1 vs -0.3 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -3.7 vs -1.2 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -3.6 vs -1.4 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.4 vs 0.5 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -3.2 vs -1.2 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -3.8 vs -0.2 5 mg · wk 104 · n 148 · Phase 3 · secondary NCT02033889
  • -3.2 vs 0.1 5 mg · wk 52 · n 181 · Phase 3 · secondary NCT02033889
  • -1.9 vs -0.3 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.4 vs -0.5 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -3.5 vs -0.9 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -3.2 vs -1.4 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -3.4 vs -1.3 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -1.3 vs 0.5 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -3.0 vs -1.2 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.8 vs -0.7 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.5 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -3.0 vs -0.9 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • -2.9 vs -0.9 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • -7.4 vs -1.0 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -4.2 vs -1.0 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.9 15 mg · wk 52 · n 440 · Phase 3 · secondary NCT01999218
  • -3.7 vs -0.7 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -3.0 vs 0.9 5 mg · wk 52 · n 448 · Phase 3 · secondary NCT01999218
  • -2.7 vs -0.7 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.9 vs -0.7 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.5 vs -0.7 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
HbA1c below 7%42.8% vs 43%vs Metformin XR300 mg · wk 26 · n 215NCT01809327
6 other results
  • 38.8% vs 43% 100 mg · wk 26 · n 206 · Phase 3 · secondary NCT01809327
  • 56.8% vs 43% wk 26 · n 213 · Phase 3 · secondary NCT01809327
  • 49.6% vs 43% wk 26 · n 224 · Phase 3 · secondary NCT01809327
  • 57.1% vs 31.5% 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • 47.8% vs 31.5% 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • 32.3% vs 12.2% wk 26 · n 96 · Phase 4 · secondary NCT02025907
28.2% vs 15.5%+12.7 vs placebo15 mg · wk 18 · n 2520NCT01986881
43 other results
  • 29% vs 17.4% 15 mg · wk 52 · n 2347 · Phase 3 · secondary NCT01986881
  • 23.8% vs 16.6% 15 mg · wk 104 · n 1541 · Phase 3 · secondary NCT01986881
  • 22.7% vs 16.9% 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • 22.7% vs 18.2% 15 mg · wk 208 · n 860 · Phase 3 · secondary NCT01986881
  • 28.4% vs 15.5% 5 mg · wk 18 · n 2544 · Phase 3 · secondary NCT01986881
  • 28.3% vs 17.4% 5 mg · wk 52 · n 2363 · Phase 3 · secondary NCT01986881
  • 23.9% vs 16.6% 5 mg · wk 104 · n 1570 · Phase 3 · secondary NCT01986881
  • 23.1% vs 16.9% 5 mg · wk 156 · n 1592 · Phase 3 · secondary NCT01986881
  • 35.8% vs 13.1% 15 mg · wk 26 · n 151 · Phase 3 · secondary NCT01958671
  • 40% vs 15.8% 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • 40.8% vs 16.2% 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • 21.1% vs 10.7% 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • 33.7% vs 19.1% 15 mg · wk 104 · n 205 · Phase 3 · secondary NCT02033889
  • 20% vs 16.5% 15 mg · wk 260 · n 529 · Phase 3 · secondary NCT01986881
  • 20.7% vs 10.7% 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • 24.9% vs 18.2% 5 mg · wk 208 · n 876 · Phase 3 · secondary NCT01986881
  • 39.9% vs 17% 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • 11.3% vs 12.1% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • 36.6% vs 30.6% 15 mg · wk 52 · n 205 · Phase 3 · secondary NCT02033889
  • 35.3% vs 15.8% 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • 34.8% vs 30.6% 5 mg · wk 52 · n 207 · Phase 3 · secondary NCT02033889
  • 24.6% vs 19.1% 5 mg · wk 104 · n 207 · Phase 3 · secondary NCT02033889
  • 18.6% vs 16.5% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • 27.8% vs 25% 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • 32.7% vs 12.8% 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • 32.7% vs 13.7% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • 28.2% vs 13.1% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • 32.1% vs 17% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • 16.2% vs 12.1% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • 38.2% vs 16.2% 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • 32.7% vs 25% 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • 37% vs 12.8% 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • 33.3% vs 13.7% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • 31.3% vs 8.3% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • 35.7% vs 8.3% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • 31.9% vs 32.8% 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • 26.4% vs 32.8% 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • 49.2% vs 32.8% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • 52.3% vs 32.8% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • 42.9% vs 15.6% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT01059825
  • 36.2% vs 15.6% 25 mg · wk 12 · n 47 · Phase 2 · secondary NCT01059825
  • 38.6% vs 15.6% 10 mg · wk 12 · n 44 · Phase 2 · secondary NCT01059825
  • 44% vs 15.6% 1 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
Fasting plasma glucose, change-0.6 vs 0.2−0.7 vs placebo300 mg · wk 338 · n 1377NCT01032629
34 other results
  • -0.4 vs 0.2 100 mg · wk 338 · n 1410 · Phase 3 · secondary NCT01032629
  • -1.1 vs 0.4 300 mg · wk 26 · n 229 · Phase 3 · secondary NCT01106651
  • -0.7 vs 0.0 300 mg · wk 26 · n 88 · Phase 3 · secondary NCT01064414
  • -1.8 vs 0.1 300 mg · wk 26 · n 112 · Phase 3 · secondary NCT01106690
  • -1.7 vs 0.2 300 mg · wk 26 · n 152 · Phase 3 · secondary NCT01106625
  • -1.9 vs 0.5 300 mg · wk 26 · n 192 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 300 mg · wk 18 · n 227 · Phase 3 · secondary NCT01381900
  • -1 vs 0.4 100 mg · wk 26 · n 239 · Phase 3 · secondary NCT01106651
  • -0.8 vs 0.0 100 mg · wk 26 · n 90 · Phase 3 · secondary NCT01064414
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -1.0 vs 0.2 100 mg · wk 26 · n 155 · Phase 3 · secondary NCT01106625
  • -1.5 vs 0.5 100 mg · wk 26 · n 188 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 100 mg · wk 18 · n 223 · Phase 3 · secondary NCT01381900
  • -1.9 vs 0.2 wk 24 · n 69 · Phase 3 · secondary NCT02354235
  • -1.9 vs -1.0 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -1.7 vs -0.3 300 mg · wk 52 · n 373 · Phase 3 · secondary NCT01137812
  • -2.1 vs -1.1 300 mg · wk 26 · n 360 · Phase 3 · secondary NCT01106677
  • -1.4 vs -1.0 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -1.5 vs -1.1 100 mg · wk 26 · n 365 · Phase 3 · secondary NCT01106677
  • 9.7 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • 10.0 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • -1.4 vs 0.2 300 mg daily · wk 12 · n 61 · Phase 2 · secondary NCT00642278
  • -1.3 vs -0.4 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -1.4 vs 0.2 100 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -0.0 vs -0.4 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -1.3 vs 0.2 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -1.5 vs 0.2 200 mg daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -0.9 vs 0.5 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.5 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.2 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -1.6 vs -0.1 wk 26 · n 103 · Phase 4 · secondary NCT02025907
  • -1.9 vs -0.1 wk 16 · n 75 · Phase 4 · secondary NCT02220920
  • -1.8 vs -1.8 n 75 · Phase 4 · secondary NCT02622113
  • 7.9 vs 8.8 wk 16 · n 15 · Phase 4 · secondary NCT02964585
-1.6 vs -0.5−1.1 vs placebo15 mg · wk 52 · n 2328NCT01986881
63 other results
  • -1.9 vs -0.9 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -1.4 vs -0.2 15 mg · wk 104 · n 1536 · Phase 3 · secondary NCT01986881
  • -1.3 vs -0.2 15 mg · wk 156 · n 1567 · Phase 3 · secondary NCT01986881
  • -0.9 vs 0.2 15 mg · wk 208 · n 861 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.5 5 mg · wk 52 · n 2352 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.9 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.2 5 mg · wk 104 · n 1562 · Phase 3 · secondary NCT01986881
  • -1.1 vs -0.2 5 mg · wk 156 · n 1579 · Phase 3 · secondary NCT01986881
  • -1.9 vs -0.7 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.5 vs 0.2 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -2.2 vs -0.1 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -1.8 vs -0.4 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -0.6 vs -0.3 15 mg · wk 260 · n 524 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.6 15 mg · wk 104 · n 144 · Phase 3 · secondary NCT02033889
  • -1.2 vs -0.7 5 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.1 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.4 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -0.8 vs 0.2 5 mg · wk 208 · n 868 · Phase 3 · secondary NCT01986881
  • -0.8 vs -0.3 5 mg · wk 260 · n 520 · Phase 3 · secondary NCT01986881
  • -2.4 vs 0.0 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -1.8 vs -0.1 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.1 vs -0.3 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.9 vs -0.4 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -1.5 vs -0.8 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -1.4 vs 0.2 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -1.9 vs 0.0 5 mg · wk 26 · n 155 · Phase 3 · secondary NCT01958671
  • -1.5 vs -0.1 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -0.7 vs -0.3 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -2.1 vs -0.4 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.6 vs -0.8 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -1.0 vs -0.6 5 mg · wk 104 · n 143 · Phase 3 · secondary NCT02033889
  • -0.7 vs 1.2 wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -1.1 vs 0.5 wk 24 · n 111 · Phase 3 · secondary NCT04029480
  • -4.7 vs 0.8 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.1 vs 0.8 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -2.0 vs -1.4 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -2.0 vs -1.4 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.7 vs -1.4 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.4 vs -1.4 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • -1.3 vs 0.1 5 mg · wk 12 · n 53 · Phase 2 · secondary NCT01059825
  • -1.4 vs 0.2 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 5 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.3 vs 0.3 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -1.3 vs -0.3 5 mg · wk 2 · n 34 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.1 25 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.5 vs 0.3 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -1.8 vs -0.3 25 mg · wk 2 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.1 10 mg · wk 12 · n 51 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.2 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.3 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -1.5 vs 0.3 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.1 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.8 vs 0.2 1 mg · wk 4 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.6 vs -0.3 1 mg · wk 2 · n 35 · Phase 2 · secondary NCT01096667
  • -0.8 vs 0.3 1 mg · wk 2 · n 51 · Phase 2 · secondary NCT01059825
3-point MACE (% with event)—Not posted · NCT04304261—Not posted · NCT03717194

HbA1c, change

Canagliflozin
-0.4% vs 0.4%−0.8 vs placebo100/300 mg · wk 26 · n 84NCT03170518
41 other results
  • -0.7% vs -0.0% 300 mg · wk 26 · n 229 · Phase 3 · primary NCT01106651
  • -0.4% vs -0.0% 300 mg · wk 26 · n 89 · Phase 3 · primary NCT01064414
  • -1.0% vs -0.3% 300 mg · wk 26 · n 112 · Phase 3 · primary NCT01106690
  • -1.1% vs -0.1% 300 mg · wk 26 · n 152 · Phase 3 · primary NCT01106625
  • -1.0% vs 0.1% 300 mg · wk 26 · n 194 · Phase 3 · primary NCT01081834
  • -1.1% vs -0.5% 300 mg · wk 18 · n 227 · Phase 3 · primary NCT01381900
  • -0.6% vs -0.0% 100 mg · wk 26 · n 239 · Phase 3 · primary NCT01106651
  • -0.3% vs -0.0% 100 mg · wk 26 · n 88 · Phase 3 · primary NCT01064414
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 26 · n 155 · Phase 3 · primary NCT01106625
  • -0.8% vs 0.1% 100 mg · wk 26 · n 191 · Phase 3 · primary NCT01081834
  • -1.0% vs -0.5% 100 mg · wk 18 · n 223 · Phase 3 · primary NCT01381900
  • -1.0% vs -0.1% wk 24 · n 70 · Phase 3 · primary NCT02354235
  • -0.9% vs -0.8% 300 mg · wk 52 · n 474 · Phase 3 · primary NCT00968812
  • -1.0% vs -0.7% 300 mg · wk 52 · n 374 · Phase 3 · primary NCT01137812
  • -1.4% vs -1.3% 300 mg · wk 26 · n 234 · Phase 3 · primary NCT01809327
  • -0.9% vs -0.8% 300 mg · wk 26 · n 360 · Phase 3 · primary NCT01106677
  • -0.8% vs -0.8% 100 mg · wk 52 · n 478 · Phase 3 · primary NCT00968812
  • -1.4% vs -1.3% 100 mg · wk 26 · n 230 · Phase 3 · primary NCT01809327
  • -0.8% vs -0.8% 100 mg · wk 26 · n 365 · Phase 3 · primary NCT01106677
  • -1.8% vs -1.3% wk 26 · n 236 · Phase 3 · primary NCT01809327
  • -1.8% vs -1.3% wk 26 · n 235 · Phase 3 · primary NCT01809327
  • -0.3% vs 0.0% 300 mg · wk 338 · n 1352 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.0% 100 mg · wk 338 · n 1392 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.7% 100/300 mg · wk 52 · n 84 · Phase 3 · secondary NCT03170518
  • -0.6% vs 0.1% 100/300 mg · wk 12 · n 84 · Phase 3 · secondary NCT03170518
  • -0.7% vs -0.6% 300 mg · wk 104 · n 474 · Phase 3 · secondary NCT00968812
  • -0.9% vs -0.7% 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 100 mg · wk 104 · n 478 · Phase 3 · secondary NCT00968812
  • -0.7% vs -0.7% 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -0.9% vs -0.2% 300 mg daily · wk 12 · n 60 · Phase 2 · primary NCT00642278
  • -0.8% vs -0.2% 100 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.2% 300 mg twice daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.7% vs -0.2% 200 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.6% vs -0.0% 150 mg Bid · wk 18 · n 91 · Phase 2 · primary NCT01340664
  • -0.5% vs -0.0% 50 mg Bid · wk 18 · n 90 · Phase 2 · primary NCT01340664
  • -0.8% vs -0.2% 50 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.0% wk 26 · n 99 · Phase 4 · primary NCT02025907
  • -1.0% vs 0.1% wk 16 · n 76 · Phase 4 · primary NCT02220920
  • -0.9% vs -1.1% n 76 · Phase 4 · secondary NCT02622113
  • 7.8% vs 8.3% wk 16 · n 15 · Phase 4 · secondary NCT02964585
Ertugliflozin
-1.0% vs 0.2%−1.2 vs placebo15 mg · wk 26 · n 151NCT01958671
65 other results
  • -0.9% vs -0.0% 15 mg · wk 26 · n 205 · Phase 3 · primary NCT02033889
  • -0.9% vs -0.1% 15 mg · wk 26 · n 153 · Phase 3 · primary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 155 · Phase 3 · primary NCT01986855
  • -0.9% vs -0.2% 15 mg · wk 26 · n 169 · Phase 3 · primary NCT02630706
  • -0.8% vs -0.2% 15 mg · wk 18 · n 370 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.2% 5 mg · wk 18 · n 348 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.6% 15 mg · wk 18 · n 54 · Phase 3 · primary NCT01986881
  • -1.0% vs -0.2% 15 mg · wk 18 · n 113 · Phase 3 · primary NCT01986881
  • -0.8% vs 0.2% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT01958671
  • -0.7% vs -0.0% 5 mg · wk 26 · n 207 · Phase 3 · primary NCT02033889
  • -0.8% vs -0.1% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 158 · Phase 3 · primary NCT01986855
  • -1% vs -0.2% 5 mg · wk 26 · n 170 · Phase 3 · primary NCT02630706
  • -0.9% vs -0.6% 5 mg · wk 18 · n 55 · Phase 3 · primary NCT01986881
  • -0.9% vs -0.2% 5 mg · wk 18 · n 100 · Phase 3 · primary NCT01986881
  • -1.7% vs -0.4% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · primary NCT02226003
  • -1.6% vs -0.4% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · primary NCT02226003
  • -0.6% vs 0.1% wk 24 · n 111 · Phase 3 · primary NCT04029480
  • -0.6% vs -0.7% 15 mg · wk 52 · n 440 · Phase 3 · primary NCT01999218
  • -1.1% vs -1.1% 15 mg · wk 26 · n 248 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 5 mg · wk 52 · n 448 · Phase 3 · primary NCT01999218
  • -1.0% vs -1.1% 5 mg · wk 26 · n 250 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · primary NCT02099110
  • -0.5% vs -0.1% 15 mg · wk 104 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 52 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 15 mg · wk 156 · n 1574 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 15 mg · wk 208 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 5 mg · wk 156 · n 1590 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.3% vs -0.1% 15 mg · wk 260 · n 527 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.7% 5 mg · wk 52 · n 179 · Phase 3 · secondary NCT02033889
  • -0.3% vs -0.1% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -0.9% vs -0.6% 15 mg · wk 104 · n 142 · Phase 3 · secondary NCT02033889
  • -1.0% vs -0.7% 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -0.6% vs -0.6% 5 mg · wk 104 · n 147 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -0.5% vs 0.3% 5 mg · wk 24 · n 85 · Phase 3 · secondary NCT04029480
  • -0.2% vs 0.8% wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -0.4% vs 0.3% wk 24 · n 89 · Phase 3 · secondary NCT04029480
  • -0.1% vs 0.2% 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.3% vs 0.2% 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -0.8% vs -0.1% 5 mg · wk 12 · n 53 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 12 · n 50 · Phase 2 · primary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 12 · n 51 · Phase 2 · primary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -0.3% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.1% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT01059825

Body weight, change (kg)

Canagliflozin
-2.9 vs -0.8−2.1 vs placebo300 mg daily · wk 12 · n 62NCT00642278
8 other results
  • -1.5 vs 0.1 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -2.3 vs -0.8 100 mg daily · wk 12 · n 64 · Phase 2 · secondary NCT00642278
  • -1.0 vs 0.1 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -2.9 vs -0.8 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -2.3 vs -0.8 200 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -2.0 vs -0.8 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -3.5 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
  • -6 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
Ertugliflozin
-3.8 vs -1.3−2.5 vs placebo15 mg · wk 208 · n 2746NCT01986881
43 other results
  • -3.4 vs -1.0 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • -3.2 vs -0.7 15 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.4 15 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.3 vs -0.4 15 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.3 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.0 5 mg · wk 156 · n 1595 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.7 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.5 vs -0.4 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.4 5 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -4.6 vs -1.2 15 mg · wk 260 · n 530 · Phase 3 · secondary NCT01986881
  • -3.6 vs -0.2 15 mg · wk 104 · n 145 · Phase 3 · secondary NCT02033889
  • -3.4 vs 0.1 15 mg · wk 52 · n 178 · Phase 3 · secondary NCT02033889
  • -2.8 vs -0.9 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -2.9 vs -1.3 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -2.1 vs -0.3 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -3.7 vs -1.2 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -3.6 vs -1.4 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.4 vs 0.5 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -3.2 vs -1.2 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -3.8 vs -0.2 5 mg · wk 104 · n 148 · Phase 3 · secondary NCT02033889
  • -3.2 vs 0.1 5 mg · wk 52 · n 181 · Phase 3 · secondary NCT02033889
  • -1.9 vs -0.3 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.4 vs -0.5 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -3.5 vs -0.9 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -3.2 vs -1.4 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -3.4 vs -1.3 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -1.3 vs 0.5 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -3.0 vs -1.2 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.8 vs -0.7 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.5 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -3.0 vs -0.9 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • -2.9 vs -0.9 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • -7.4 vs -1.0 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -4.2 vs -1.0 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.9 15 mg · wk 52 · n 440 · Phase 3 · secondary NCT01999218
  • -3.7 vs -0.7 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -3.0 vs 0.9 5 mg · wk 52 · n 448 · Phase 3 · secondary NCT01999218
  • -2.7 vs -0.7 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.9 vs -0.7 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.5 vs -0.7 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110

HbA1c below 7%

Canagliflozin
42.8% vs 43%vs Metformin XR300 mg · wk 26 · n 215NCT01809327
6 other results
  • 38.8% vs 43% 100 mg · wk 26 · n 206 · Phase 3 · secondary NCT01809327
  • 56.8% vs 43% wk 26 · n 213 · Phase 3 · secondary NCT01809327
  • 49.6% vs 43% wk 26 · n 224 · Phase 3 · secondary NCT01809327
  • 57.1% vs 31.5% 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • 47.8% vs 31.5% 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • 32.3% vs 12.2% wk 26 · n 96 · Phase 4 · secondary NCT02025907
Ertugliflozin
28.2% vs 15.5%+12.7 vs placebo15 mg · wk 18 · n 2520NCT01986881
43 other results
  • 29% vs 17.4% 15 mg · wk 52 · n 2347 · Phase 3 · secondary NCT01986881
  • 23.8% vs 16.6% 15 mg · wk 104 · n 1541 · Phase 3 · secondary NCT01986881
  • 22.7% vs 16.9% 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • 22.7% vs 18.2% 15 mg · wk 208 · n 860 · Phase 3 · secondary NCT01986881
  • 28.4% vs 15.5% 5 mg · wk 18 · n 2544 · Phase 3 · secondary NCT01986881
  • 28.3% vs 17.4% 5 mg · wk 52 · n 2363 · Phase 3 · secondary NCT01986881
  • 23.9% vs 16.6% 5 mg · wk 104 · n 1570 · Phase 3 · secondary NCT01986881
  • 23.1% vs 16.9% 5 mg · wk 156 · n 1592 · Phase 3 · secondary NCT01986881
  • 35.8% vs 13.1% 15 mg · wk 26 · n 151 · Phase 3 · secondary NCT01958671
  • 40% vs 15.8% 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • 40.8% vs 16.2% 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • 21.1% vs 10.7% 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • 33.7% vs 19.1% 15 mg · wk 104 · n 205 · Phase 3 · secondary NCT02033889
  • 20% vs 16.5% 15 mg · wk 260 · n 529 · Phase 3 · secondary NCT01986881
  • 20.7% vs 10.7% 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • 24.9% vs 18.2% 5 mg · wk 208 · n 876 · Phase 3 · secondary NCT01986881
  • 39.9% vs 17% 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • 11.3% vs 12.1% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • 36.6% vs 30.6% 15 mg · wk 52 · n 205 · Phase 3 · secondary NCT02033889
  • 35.3% vs 15.8% 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • 34.8% vs 30.6% 5 mg · wk 52 · n 207 · Phase 3 · secondary NCT02033889
  • 24.6% vs 19.1% 5 mg · wk 104 · n 207 · Phase 3 · secondary NCT02033889
  • 18.6% vs 16.5% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • 27.8% vs 25% 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • 32.7% vs 12.8% 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • 32.7% vs 13.7% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • 28.2% vs 13.1% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • 32.1% vs 17% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • 16.2% vs 12.1% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • 38.2% vs 16.2% 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • 32.7% vs 25% 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • 37% vs 12.8% 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • 33.3% vs 13.7% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • 31.3% vs 8.3% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • 35.7% vs 8.3% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • 31.9% vs 32.8% 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • 26.4% vs 32.8% 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • 49.2% vs 32.8% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • 52.3% vs 32.8% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • 42.9% vs 15.6% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT01059825
  • 36.2% vs 15.6% 25 mg · wk 12 · n 47 · Phase 2 · secondary NCT01059825
  • 38.6% vs 15.6% 10 mg · wk 12 · n 44 · Phase 2 · secondary NCT01059825
  • 44% vs 15.6% 1 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825

Fasting plasma glucose, change

Canagliflozin
-0.6 vs 0.2−0.7 vs placebo300 mg · wk 338 · n 1377NCT01032629
34 other results
  • -0.4 vs 0.2 100 mg · wk 338 · n 1410 · Phase 3 · secondary NCT01032629
  • -1.1 vs 0.4 300 mg · wk 26 · n 229 · Phase 3 · secondary NCT01106651
  • -0.7 vs 0.0 300 mg · wk 26 · n 88 · Phase 3 · secondary NCT01064414
  • -1.8 vs 0.1 300 mg · wk 26 · n 112 · Phase 3 · secondary NCT01106690
  • -1.7 vs 0.2 300 mg · wk 26 · n 152 · Phase 3 · secondary NCT01106625
  • -1.9 vs 0.5 300 mg · wk 26 · n 192 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 300 mg · wk 18 · n 227 · Phase 3 · secondary NCT01381900
  • -1 vs 0.4 100 mg · wk 26 · n 239 · Phase 3 · secondary NCT01106651
  • -0.8 vs 0.0 100 mg · wk 26 · n 90 · Phase 3 · secondary NCT01064414
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -1.0 vs 0.2 100 mg · wk 26 · n 155 · Phase 3 · secondary NCT01106625
  • -1.5 vs 0.5 100 mg · wk 26 · n 188 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 100 mg · wk 18 · n 223 · Phase 3 · secondary NCT01381900
  • -1.9 vs 0.2 wk 24 · n 69 · Phase 3 · secondary NCT02354235
  • -1.9 vs -1.0 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -1.7 vs -0.3 300 mg · wk 52 · n 373 · Phase 3 · secondary NCT01137812
  • -2.1 vs -1.1 300 mg · wk 26 · n 360 · Phase 3 · secondary NCT01106677
  • -1.4 vs -1.0 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -1.5 vs -1.1 100 mg · wk 26 · n 365 · Phase 3 · secondary NCT01106677
  • 9.7 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • 10.0 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • -1.4 vs 0.2 300 mg daily · wk 12 · n 61 · Phase 2 · secondary NCT00642278
  • -1.3 vs -0.4 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -1.4 vs 0.2 100 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -0.0 vs -0.4 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -1.3 vs 0.2 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -1.5 vs 0.2 200 mg daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -0.9 vs 0.5 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.5 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.2 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -1.6 vs -0.1 wk 26 · n 103 · Phase 4 · secondary NCT02025907
  • -1.9 vs -0.1 wk 16 · n 75 · Phase 4 · secondary NCT02220920
  • -1.8 vs -1.8 n 75 · Phase 4 · secondary NCT02622113
  • 7.9 vs 8.8 wk 16 · n 15 · Phase 4 · secondary NCT02964585
Ertugliflozin
-1.6 vs -0.5−1.1 vs placebo15 mg · wk 52 · n 2328NCT01986881
63 other results
  • -1.9 vs -0.9 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -1.4 vs -0.2 15 mg · wk 104 · n 1536 · Phase 3 · secondary NCT01986881
  • -1.3 vs -0.2 15 mg · wk 156 · n 1567 · Phase 3 · secondary NCT01986881
  • -0.9 vs 0.2 15 mg · wk 208 · n 861 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.5 5 mg · wk 52 · n 2352 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.9 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.2 5 mg · wk 104 · n 1562 · Phase 3 · secondary NCT01986881
  • -1.1 vs -0.2 5 mg · wk 156 · n 1579 · Phase 3 · secondary NCT01986881
  • -1.9 vs -0.7 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.5 vs 0.2 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -2.2 vs -0.1 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -1.8 vs -0.4 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -0.6 vs -0.3 15 mg · wk 260 · n 524 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.6 15 mg · wk 104 · n 144 · Phase 3 · secondary NCT02033889
  • -1.2 vs -0.7 5 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.1 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.4 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -0.8 vs 0.2 5 mg · wk 208 · n 868 · Phase 3 · secondary NCT01986881
  • -0.8 vs -0.3 5 mg · wk 260 · n 520 · Phase 3 · secondary NCT01986881
  • -2.4 vs 0.0 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -1.8 vs -0.1 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.1 vs -0.3 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.9 vs -0.4 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -1.5 vs -0.8 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -1.4 vs 0.2 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -1.9 vs 0.0 5 mg · wk 26 · n 155 · Phase 3 · secondary NCT01958671
  • -1.5 vs -0.1 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -0.7 vs -0.3 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -2.1 vs -0.4 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.6 vs -0.8 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -1.0 vs -0.6 5 mg · wk 104 · n 143 · Phase 3 · secondary NCT02033889
  • -0.7 vs 1.2 wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -1.1 vs 0.5 wk 24 · n 111 · Phase 3 · secondary NCT04029480
  • -4.7 vs 0.8 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.1 vs 0.8 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -2.0 vs -1.4 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -2.0 vs -1.4 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.7 vs -1.4 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.4 vs -1.4 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • -1.3 vs 0.1 5 mg · wk 12 · n 53 · Phase 2 · secondary NCT01059825
  • -1.4 vs 0.2 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 5 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.3 vs 0.3 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -1.3 vs -0.3 5 mg · wk 2 · n 34 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.1 25 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.5 vs 0.3 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -1.8 vs -0.3 25 mg · wk 2 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.1 10 mg · wk 12 · n 51 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.2 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.3 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -1.5 vs 0.3 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.1 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.8 vs 0.2 1 mg · wk 4 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.6 vs -0.3 1 mg · wk 2 · n 35 · Phase 2 · secondary NCT01096667
  • -0.8 vs 0.3 1 mg · wk 2 · n 51 · Phase 2 · secondary NCT01059825

3-point MACE (% with event)

Canagliflozin
—Not posted · NCT04304261
Ertugliflozin
—Not posted · NCT03717194
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
13 other shared endpoints and safety

Coverage. Canagliflozin: 17 of 17 rows · Ertugliflozin: 17 of 17 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCanagliflozin
Rows use multiple source trials
Ertugliflozin
Rows use multiple source trials
Ambulatory Day DBP
absolute change · mmHg
-3.23 vs -0.2 placebo mmHg @ 6wk300 mga,b,c,d,e
NCT01939496 · Phase 4 · registry result, not featured evidence
show 1 more dose
-2.39 vs -0.2 placebo mmHg @ 6wk100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-1.88 vs 0.87 placebo mmHg @ 4wk5 mga,b,c,d,e
NCT01096667 · Phase 2 · registry result, not featured evidence
show 2 more doses
-1.77 vs 0.87 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-2.12 vs 0.87 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
Ambulatory Day SBP
absolute change · mmHg
-7.36 vs -0.65 placebo mmHg @ 6wk300 mga,b,c,d,e
NCT01939496 · Phase 4 · registry result, not featured evidence
show 1 more dose
-5.05 vs -0.65 placebo mmHg @ 6wk100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-3.61 vs 0.82 placebo mmHg @ 4wk5 mga,b,c,d,e
NCT01096667 · Phase 2 · registry result, not featured evidence
show 2 more doses
-4.17 vs 0.82 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-2.88 vs 0.82 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
Ambulatory DBP
absolute change · mmHg
-3.27 vs -0.26 placebo mmHg @ 6wk300 mga,b,c,d,e
NCT01939496 · Phase 4 · registry result, not featured evidence
show 1 more dose
-2.18 vs -0.26 placebo mmHg @ 6wk100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-2.34 vs 0.77 placebo mmHg @ 4wk5 mga,b,c,d,e
NCT01096667 · Phase 2 · registry result, not featured evidence
show 2 more doses
-1.5 vs 0.77 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-1.89 vs 0.77 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
Ambulatory Night DBP
absolute change · mmHg
-3.42 vs -0.98 placebo mmHg @ 6wk300 mga,b,c,d,e
NCT01939496 · Phase 4 · registry result, not featured evidence
show 1 more dose
-1.73 vs -0.98 placebo mmHg @ 6wk100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-2.52 vs 1.02 placebo mmHg @ 4wk5 mga,b,c,d,e
NCT01096667 · Phase 2 · registry result, not featured evidence
show 2 more doses
-0.84 vs 1.02 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-1.48 vs 1.02 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
Ambulatory Night SBP
absolute change · mmHg
-6.98 vs -3.49 placebo mmHg @ 6wk300 mga,b,c,d,e
NCT01939496 · Phase 4 · registry result, not featured evidence
show 1 more dose
-4.33 vs -3.49 placebo mmHg @ 6wk100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-3.47 vs -0.29 placebo mmHg @ 4wk5 mga,b,c,d,e
NCT01096667 · Phase 2 · registry result, not featured evidence
show 2 more doses
-2.31 vs -0.29 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-2.48 vs -0.29 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
Ambulatory SBP
absolute change · mmHg
-7.31 vs -1.26 placebo mmHg @ 6wk300 mga,b,c,d,e
NCT01939496 · Phase 4 · registry result, not featured evidence
show 1 more dose
-4.78 vs -1.26 placebo mmHg @ 6wk100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-3.73 vs 0.26 placebo mmHg @ 4wk5 mga,b,c,d,e
NCT01096667 · Phase 2 · registry result, not featured evidence
show 2 more doses
-3.42 vs 0.26 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-2.71 vs 0.26 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
eGFR
absolute change · mL
-3.98 vs -5.23 placebo mL @ 338wk300 mga,f,g,h
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more dose
-3.55 vs -5.23 placebo mL @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.2 vs -1.8 placebo mL @ 312wk15 mga,f,g,h
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more dose
3.7 vs -1.8 placebo mL @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Plasma Glucose Change mg/dL
absolute change · mg
-11.5 vs 15.3 placebo mg @ 26wk100/300 mgi,d
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-55.36 vs -9.3 placebo mg @ 26wk15 mg + 100 mga,i,d
NCT02226003 · Phase 3 · combination
show 1 more dose
-48.25 vs -9.3 placebo mg @ 26wk5 mg + 100 mg
NCT02226003 · Phase 3 · combination
Glycemic Rescue
responder rate · % of participants
11.9% (n=84) vs 46% (n=87) placebo100/300 mgi,d,j
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
10.7% (n=205) vs 24.4% (n=209) placebo @ 104wk15 mga,i,d,j
NCT02033889 · Phase 3
show 1 more dose
11.1% (n=207) vs 24.4% (n=209) placebo @ 104wk5 mg
NCT02033889 · Phase 3
SBP
absolute change · mmHg
-5.76 vs 0.09 placebo mmHg @ 26wkk,c,d
NCT02025907 · Phase 4 · registry result, not featured evidence
14 other source trials
-2.24 vs -0.33 Metformin XR mmHg @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-2.24 vs -0.33 Metformin XR mmHg @ 26wk100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-2.36 vs -0.33 Metformin XR mmHg @ 26wk300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-1.65 vs -0.33 Metformin XR mmHg @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-3.52 vs 1.1 placebo mmHg @ 26wk100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-6.79 vs 1.1 placebo mmHg @ 26wk300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-5.3 vs -1.24 placebo mmHg @ 26wk100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-4.7 vs -1.24 placebo mmHg @ 26wk300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-3.84 vs -1.83 Sitagliptin mmHg @ 26wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-5.06 vs -1.83 Sitagliptin mmHg @ 26wk300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-4.89 vs -2.65 placebo mmHg @ 26wk100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-4.27 vs -2.65 placebo mmHg @ 26wk300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-3.34 vs 0.38 placebo mmHg @ 26wk100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-5.04 vs 0.38 placebo mmHg @ 26wk300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-3.98 vs 2.41 placebo mmHg @ 26wk15 mg + 100 mga,k,c,d
NCT02226003 · Phase 3 · combination
show 1 more dose
-2.04 vs 2.41 placebo mmHg @ 26wk5 mg + 100 mg
NCT02226003 · Phase 3 · combination
Seated DBP
absolute change · mmHg
-0.2 vs 0.7 placebo mmHg @ 52wk100/300 mgl,d
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-0.95 vs -0.15 placebo mmHg @ 52wk15 mga,l,d
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more dose
-0.97 vs -0.15 placebo mmHg @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Seated SBP
absolute change · mmHg
0 vs 1.5 placebo mmHg @ 52wk100/300 mgl,d
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-2.41 vs 0.75 placebo mmHg @ 52wk15 mga,l,d
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more dose
-1.84 vs 0.75 placebo mmHg @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Weight
percent change · % of baseline
-2.14% (n=75) vs -1.4% (n=65) placebob,c,d,j
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
5 other source trials
-2.6% (n=64) vs -1.1% (n=62) placebo @ 12wk100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-2.7% (n=63) vs -1.1% (n=62) placebo @ 12wk200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-2.3% (n=63) vs -1.1% (n=62) placebo @ 12wk50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-2.5% (n=53) vs -0.75% (n=51) placebo @ 12wk5 mga,b,c,d,j
NCT01059825 · Phase 2 · registry result, not featured evidence
show 3 more doses
-2.66% (n=50) vs -0.75% (n=51) placebo @ 12wk25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
-2.9% (n=51) vs -0.75% (n=51) placebo @ 12wk10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
-1.9% (n=54) vs -0.75% (n=51) placebo @ 12wk1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
Dropout rate
6.1%300 mgm
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
7%100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
33.4%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
29%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
10.4%100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
0.7%100 mg
NCT02065791 · Phase 3
0%
NCT02964585 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT02920918 · Phase 4 · registry result, not featured evidence
1.2%
NCT01989754 · Phase 4 · registry result, not featured evidence
13.2%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
11.1%
NCT02025907 · Phase 4 · registry result, not featured evidence
3.9%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
3.6%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
5.3%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
4.3%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
9.2%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
11%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
10.5%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
5.1%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
24.6%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
23.7%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
5.3%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
4%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
7.9%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
16.7%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.4%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
8%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
12%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
12.5%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
17.3%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
17.8%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
32.6%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
14%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
8.6%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
12.5%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.8%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
10.9%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
13.8%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.8%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
6.7%Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
13.3%Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
—15 mgn
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.6%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.8%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2%15 mg
NCT02033889 · Phase 3
9.7%5 mg
NCT02033889 · Phase 3
22.9%15 mg
NCT01999218 · Phase 3
24.3%5 mg
NCT01999218 · Phase 3
12.5%15 mg
NCT02099110 · Phase 3
9.6%5 mg
NCT02099110 · Phase 3
11%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
9.1%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
7.7%15 mg
NCT02036515 · Phase 3
—15 mg
NCT02036515 · Phase 3 · combination
3.2%5 mg
NCT02036515 · Phase 3
—5 mg
NCT02036515 · Phase 3 · combination
1%15 mg + 100 mg
NCT02226003 · Phase 3 · combination
2%5 mg + 100 mg
NCT02226003 · Phase 3 · combination
9%15 mg
NCT01986855 · Phase 3
8.2%5 mg
NCT01986855 · Phase 3
—15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
5.3%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
4.1%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
0%
NCT03416270 · Phase 2 · registry result, not featured evidence
5.3%5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
7.7%25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
5.1%1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
39.3%
NCT04167761 · Phase 1 · registry result, not featured evidence
—15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—300 mgm
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
—100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.5%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.2%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
—100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
—100 mg
NCT02065791 · Phase 3
—
NCT02964585 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT02920918 · Phase 4 · registry result, not featured evidence
—
NCT01989754 · Phase 4 · registry result, not featured evidence
5.3%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
5.6%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
0.9%
NCT02025907 · Phase 4 · registry result, not featured evidence
1.3%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
0%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
4.6%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
2.9%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.3%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
3.4%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
1.7%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
9.7%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.7%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.1%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.7%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.2%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
4.4%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
0.9%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
1.6%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
4.9%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
5.1%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
5.1%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
5.6%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
7.5%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
1.1%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
3.1%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
4.7%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
3.1%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.5%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
—Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
—Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
—15 mgn
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.7%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.6%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.5%15 mg
NCT02033889 · Phase 3
0.5%5 mg
NCT02033889 · Phase 3
1.6%15 mg
NCT01999218 · Phase 3
2%5 mg
NCT01999218 · Phase 3
2%15 mg
NCT02099110 · Phase 3
1.2%5 mg
NCT02099110 · Phase 3
0.8%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
1.2%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
0.6%15 mg
NCT02036515 · Phase 3
—15 mg
NCT02036515 · Phase 3 · combination
0.6%5 mg
NCT02036515 · Phase 3
—5 mg
NCT02036515 · Phase 3 · combination
—15 mg + 100 mg
NCT02226003 · Phase 3 · combination
—5 mg + 100 mg
NCT02226003 · Phase 3 · combination
0%15 mg
NCT01986855 · Phase 3
0.6%5 mg
NCT01986855 · Phase 3
—15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
0.6%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
1.2%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
—
NCT03416270 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—
NCT04167761 · Phase 1 · registry result, not featured evidence
—15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Serious AEs
42.1%300 mgm
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
41.6%100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.7%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.4%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.7%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.9%300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
10.4%100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
33.5%100 mg
NCT02065791 · Phase 3
0%
NCT02964585 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
17.6%
NCT02920918 · Phase 4 · registry result, not featured evidence
24.6%
NCT01989754 · Phase 4 · registry result, not featured evidence
9.3%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
7%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
1.9%
NCT02025907 · Phase 4 · registry result, not featured evidence
4%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
0%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
1.4%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
2.9%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.7%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.7%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
3%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
18.2%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.4%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
16.6%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
1.8%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.2%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.2%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
23.6%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.1%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
20%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
6.1%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
2.7%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
7.1%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
2.7%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
3.3%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
3.3%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
3.8%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
5.1%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
3.2%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
4.5%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
2.3%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
1%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
2.5%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
5.6%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
6.4%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
3.2%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
0%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
1.6%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.5%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
6.7%Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
0%Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
7.3%15 mgn
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
7.1%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
34.1%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.9%15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.5%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
34.9%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.3%5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.9%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.1%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.8%15 mg
NCT02033889 · Phase 3
9.7%5 mg
NCT02033889 · Phase 3
7.4%15 mg
NCT01999218 · Phase 3
9.2%5 mg
NCT01999218 · Phase 3
2%15 mg
NCT02099110 · Phase 3
4.8%5 mg
NCT02099110 · Phase 3
4.9%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
3.7%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
—15 mg
NCT02036515 · Phase 3
2%15 mg
NCT02036515 · Phase 3 · combination
—5 mg
NCT02036515 · Phase 3
8.3%5 mg
NCT02036515 · Phase 3 · combination
3.1%15 mg + 100 mg
NCT02226003 · Phase 3 · combination
2%5 mg + 100 mg
NCT02226003 · Phase 3 · combination
19.4%15 mg
NCT01986855 · Phase 3
16.5%5 mg
NCT01986855 · Phase 3
3.8%15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
3.2%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
4.5%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
5.9%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
5.3%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
17.6%
NCT03416270 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
3.6%5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
1.8%25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%
NCT04167761 · Phase 1 · registry result, not featured evidence
0%15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
300 mgm
hypoglycaemia 14.6% (placebo 12.1%)
nasopharyngitis 14.1% (placebo 15.3%)
urinary tract infection 11% (placebo 8.9%)
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 59 more results
100 mg
nasopharyngitis 15.6% (placebo 15.3%)
hypoglycaemia 12.5% (placebo 12.1%)
upper respiratory tract infection 10.9% (placebo 11.3%)
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
300 mg
nasopharyngitis 11.3%
diarrhoea 8%
upper respiratory tract infection 7.8%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
300 mg
nasopharyngitis 7.6%
diarrhoea 6.8%
upper respiratory tract infection 5.6%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
nasopharyngitis 9.7%
urinary tract infection 9.1%
upper respiratory tract infection 7.5%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
nasopharyngitis 6.8%
back pain 6%
urinary tract infection 5.4%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
300 mg
urinary tract infection 29.4% (placebo 4.6%)
urinary tract infection 29.4% (placebo 4.6%)
nausea 11.8% (placebo 1.1%)
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
100 mg
headache 11.9% (placebo 3.4%)
headache 11.9% (placebo 3.4%)
nasopharyngitis 11.9% (placebo 5.7%)
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
100 mg
hypoglycaemia 9.7% (placebo 10.3%)
urinary tract infection 9.2% (placebo 8.4%)
hypertension 6.5% (placebo 8.8%)
NCT02065791 · Phase 3
300 mg
fatigue 3.2%
diarrhoea 1.6%
discomfort 1.6%
NCT03267576 · Phase 4 · registry result, not featured evidence
acute kidney injury 17.6%
hypotensive event 11.8%
arrhythmic events 5.9%
NCT02920918 · Phase 4 · registry result, not featured evidence
balanoposthitis 3.2% (placebo 0.9%)
NCT01989754 · Phase 4 · registry result, not featured evidence
blood glucose decreased 40% (placebo 23.9%)
hypoglycaemia 38.7% (placebo 32.8%)
nasopharyngitis 34.7% (placebo 25.4%)
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 33.8%
gastroenteritis 9.9%
hypoglycaemia 9.9%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 5.6% (placebo 5.6%)
back pain 2.8% (placebo 0.9%)
depression 2.8% (placebo 0%)
NCT02025907 · Phase 4 · registry result, not featured evidence
blood glucose decreased 26.7% (placebo 16.9%)
hypoglycaemia 25.3% (placebo 21.1%)
nasopharyngitis 16% (placebo 18.3%)
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
300 mg
pollakiuria 5.4% (placebo 1.8%)
nasopharyngitis 0% (placebo 0%)
NCT01939496 · Phase 4 · registry result, not featured evidence
100 mg
nasopharyngitis 5.3% (placebo 0%)
pollakiuria 1.8% (placebo 1.8%)
NCT01939496 · Phase 4 · registry result, not featured evidence
nasopharyngitis 30.7%
pollakiuria 6.5%
constipation 5.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 18.6% (placebo 16.2%)
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
300 mg
nasopharyngitis 3.8%
upper respiratory tract infection 2.5%
back pain 2.1%
NCT01809327 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 3.8%
glomerular filtration rate decreased 2.5%
influenza 2.5%
NCT01809327 · Phase 3 · registry result, not featured evidence
diarrhoea 4.2%
headache 3%
influenza 3%
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 4.2%
headache 3.8%
influenza 3.4%
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
300 mg
nasopharyngitis 18.6% (placebo 15.2%)
hypoglycaemia 15.3% (placebo 19.8%)
urinary tract infection 14.8% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 9.7% (placebo 19.8%)
nasopharyngitis 8.1% (placebo 15.2%)
urinary tract infection 7.2% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 18.7% (placebo 15.2%)
hypoglycaemia 15.4% (placebo 19.8%)
urinary tract infection 13.3% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 10.4% (placebo 19.8%)
nasopharyngitis 9.5% (placebo 15.2%)
influenza 5.8% (placebo 7.6%)
NCT01106651 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 7.5% (placebo 4%)
upper respiratory tract infection 5.7% (placebo 6.2%)
NCT01381900 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 9% (placebo 4%)
upper respiratory tract infection 3.1% (placebo 6.2%)
NCT01381900 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 11.2% (placebo 4.4%)
nasopharyngitis 7.9% (placebo 11.1%)
urinary tract infection 7.9% (placebo 5.6%)
NCT01064414 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 22.5% (placebo 4.4%)
urinary tract infection 13.5% (placebo 5.6%)
nasopharyngitis 10.1% (placebo 11.1%)
NCT01064414 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 14.4% (placebo 4.4%)
arthralgia 4.4% (placebo 2.2%)
bronchitis 4.4% (placebo 3.3%)
NCT01064414 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 20% (placebo 4.4%)
arthralgia 5.6% (placebo 2.2%)
bronchitis 5.6% (placebo 3.3%)
NCT01064414 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 9.6% (placebo 5.2%)
pollakiuria 6.1% (placebo 0.9%)
arthralgia 5.3% (placebo 1.7%)
NCT01106690 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 13.2% (placebo 5.2%)
arthralgia 7.9% (placebo 1.7%)
urinary tract infection 7.9% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 8% (placebo 6.1%)
back pain 7.1% (placebo 2.6%)
nasopharyngitis 5.3% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 12.4% (placebo 6.1%)
nasopharyngitis 9.7% (placebo 5.2%)
back pain 8.8% (placebo 2.6%)
NCT01106690 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 4.9%
upper respiratory tract infection 4.9%
urinary tract infection 3.5%
NCT01106677 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 6.3%
upper respiratory tract infection 6.3%
urinary tract infection 4.6%
NCT01106677 · Phase 3 · registry result, not featured evidence
100 mg
pollakiuria 5.7%
urinary tract infection 4.9%
nasopharyngitis 4.1%
NCT01106677 · Phase 3 · registry result, not featured evidence
100 mg
urinary tract infection 7.3%
pollakiuria 5.7%
headache 5.2%
NCT01106677 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 6.4% (placebo 3.2%)
hypoglycaemia 5.8% (placebo 3.8%)
nasopharyngitis 5.1% (placebo 2.6%)
NCT01106625 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 7.1% (placebo 3.2%)
hypoglycaemia 7.1% (placebo 3.8%)
nasopharyngitis 5.8% (placebo 2.6%)
NCT01106625 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 10.8% (placebo 6.4%)
hypoglycaemia 7% (placebo 3.8%)
urinary tract infection 5.7% (placebo 5.1%)
NCT01106625 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 13.4% (placebo 6.4%)
hypoglycaemia 8.3% (placebo 3.8%)
urinary tract infection 7.6% (placebo 5.1%)
NCT01106625 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 6.8% (placebo 5.2%)
pain in extremity 6.8% (placebo 0%)
urinary tract infection 4.5% (placebo 4.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 8.1% (placebo 5.2%)
back pain 6.1% (placebo 3.1%)
headache 6.1% (placebo 3.6%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 10.2% (placebo 5.2%)
headache 8.6% (placebo 3.6%)
back pain 7.6% (placebo 3.1%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
urinary tract infection 6.4% (placebo 4.2%)
nasopharyngitis 4.3% (placebo 5.2%)
pain in extremity 2.1% (placebo 0%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
headache 7.2% (placebo 3.6%)
urinary tract infection 7.2% (placebo 4.2%)
nasopharyngitis 5.1% (placebo 5.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
headache 9.7% (placebo 3.6%)
urinary tract infection 8.2% (placebo 4.2%)
nasopharyngitis 7.2% (placebo 5.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 17.5%
nasopharyngitis 8.8%
upper respiratory tract infection 8.8%
NCT01137812 · Phase 3 · registry result, not featured evidence
300 mg daily
headache 4.7% (placebo 3.1%)
nausea 4.7% (placebo 0%)
abdominal pain upper 3.1% (placebo 1.5%)
NCT00642278 · Phase 2 · registry result, not featured evidence
100 mg daily
headache 7.8% (placebo 3.1%)
urinary tract infection 3.1% (placebo 6.2%)
vulvovaginal mycotic infection 3.1% (placebo 0%)
NCT00642278 · Phase 2 · registry result, not featured evidence
300 mg twice daily
nausea 7.8% (placebo 0%)
abdominal pain upper 6.3% (placebo 1.5%)
urinary tract infection 4.7% (placebo 6.2%)
NCT00642278 · Phase 2 · registry result, not featured evidence
200 mg daily
urinary tract infection 9.2% (placebo 6.2%)
vulvovaginal mycotic infection 6.2% (placebo 0%)
headache 3.1% (placebo 3.1%)
NCT00642278 · Phase 2 · registry result, not featured evidence
50 mg daily
nasopharyngitis 7.8% (placebo 3.1%)
vulvovaginal mycotic infection 6.3% (placebo 0%)
nausea 4.7% (placebo 0%)
NCT00642278 · Phase 2 · registry result, not featured evidence
urinary frequency increased 86.7%
dry mouth 26.7%
light-headedness/dizziness 26.7%
NCT02324842 · Phase na · registry result, not featured evidence
nausea 53.3%
dry mouth 40%
constipation 33.3%
NCT02324842 · Phase na · registry result, not featured evidence · combination
15 mgn
hypoglycaemia 30.3% (placebo 31.4%)
nasopharyngitis 3.5% (placebo 3.2%)
upper respiratory tract infection 2.7% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 44 more results
15 mg
hypoglycaemia 16.8% (placebo 31.4%)
nasopharyngitis 4.4% (placebo 3.2%)
dizziness 3.5% (placebo 1.2%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
hypoglycaemia 31.1% (placebo 31.4%)
urinary tract infection 9.5% (placebo 2%)
nasopharyngitis 7.4% (placebo 3.2%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
hypoglycaemia 5.6% (placebo 31.4%)
urinary tract infection 1.9% (placebo 2%)
back pain 0% (placebo 0.6%)
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 29% (placebo 31.4%)
dizziness 2.3% (placebo 1.2%)
upper respiratory tract infection 2.3% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 13% (placebo 31.4%)
hypertension 4% (placebo 0.6%)
hyperglycaemia 3% (placebo 1.7%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 32.2% (placebo 31.4%)
urinary tract infection 9.3% (placebo 2%)
upper respiratory tract infection 7.2% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 5.5% (placebo 31.4%)
back pain 3.6% (placebo 0.6%)
hypertension 3.6% (placebo 0.6%)
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15 mg
nasopharyngitis 7.2% (placebo 3.9%)
upper respiratory tract infection 6.6% (placebo 5.9%)
urinary tract infection 6.6% (placebo 12.4%)
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
urinary tract infection 8.3% (placebo 12.4%)
vulvovaginal mycotic infection 7.7% (placebo 1.3%)
constipation 7.1% (placebo 2.6%)
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
upper respiratory tract infection 10.2% (placebo 15.8%)
back pain 9.8% (placebo 4.8%)
hypoglycaemia 8.8% (placebo 20.6%)
NCT02033889 · Phase 3
5 mg
upper respiratory tract infection 11.1% (placebo 15.8%)
headache 6.8% (placebo 4.8%)
hypoglycaemia 6.8% (placebo 20.6%)
NCT02033889 · Phase 3
15 mg
urinary tract infection 6.4%
hypoglycaemia 5.7%
headache 4.4%
NCT01999218 · Phase 3
5 mg
upper respiratory tract infection 6.1%
urinary tract infection 6.1%
headache 5.6%
NCT01999218 · Phase 3
15 mg
urinary tract infection 7.7%
hypoglycaemia 5.2%
nasopharyngitis 5.2%
NCT02099110 · Phase 3
5 mg
urinary tract infection 8%
hypoglycaemia 4.8%
nasopharyngitis 2.4%
NCT02099110 · Phase 3
15 mg + 100 mg
hypoglycaemia 8.2%
nasopharyngitis 4.9%
urinary tract infection 3.3%
NCT02099110 · Phase 3 · combination
5 mg + 100 mg
urinary tract infection 5.8%
nasopharyngitis 4.9%
hypoglycaemia 3.7%
NCT02099110 · Phase 3 · combination
15 mg
nasopharyngitis 3.9% (placebo 3.3%)
hypoglycaemia 3.3% (placebo 7.2%)
urinary tract infection 3.3% (placebo 5.2%)
NCT02036515 · Phase 3 · combination
5 mg
back pain 5.1% (placebo 3.9%)
nasopharyngitis 5.1% (placebo 3.3%)
hypoglycaemia 4.5% (placebo 7.2%)
NCT02036515 · Phase 3 · combination
15 mg + 100 mg
urinary tract infection 2.1% (placebo 1%)
hyperglycaemia 1% (placebo 6.2%)
blood glucose increased 0% (placebo 7.2%)
NCT02226003 · Phase 3 · combination
5 mg + 100 mg
urinary tract infection 5.1% (placebo 1%)
blood glucose increased 3.1% (placebo 7.2%)
hyperglycaemia 0% (placebo 6.2%)
NCT02226003 · Phase 3 · combination
15 mg
hypoglycaemia 20.6% (placebo 29.2%)
urinary tract infection 7.7% (placebo 9.7%)
upper respiratory tract infection 7.1% (placebo 4.5%)
NCT01986855 · Phase 3
5 mg
hypoglycaemia 31% (placebo 29.2%)
diarrhoea 6.3% (placebo 5.8%)
cough 5.7% (placebo 1.3%)
NCT01986855 · Phase 3
15 mg
hypoglycaemia 19.2% (placebo 12.7%)
nausea 15.4% (placebo 7.3%)
vomiting 15.4% (placebo 5.5%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 14.3% (placebo 10.9%)
hypoglycaemia 11.1% (placebo 12.7%)
covid-19 7.9% (placebo 7.3%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
hypoglycaemia 11.5% (placebo 12.7%)
nausea 7.7% (placebo 7.3%)
vomiting 7.7% (placebo 5.5%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
nausea 13.6% (placebo 7.3%)
abdominal pain 9.1% (placebo 5.5%)
diarrhoea 9.1% (placebo 7.3%)
NCT04029480 · Phase 3 · registry result, not featured evidence
15 mg
hyperuricaemia 5.3% (placebo 12%)
hypoglycaemia 5.3% (placebo 1.2%)
nasopharyngitis 5.3% (placebo 6.6%)
NCT02630706 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 5.3% (placebo 6.6%)
hypoglycaemia 3.5% (placebo 1.2%)
hyperuricaemia 2.9% (placebo 12%)
NCT02630706 · Phase 3 · registry result, not featured evidence
5 mg
genital infection fungal 7.9% (placebo 0%)
athralgia 5.3% (placebo 0%)
nasopharyngitis 5.3% (placebo 0%)
NCT01096667 · Phase 2 · registry result, not featured evidence
25 mg
fatigue 5.1% (placebo 0%)
polyuria 5.1% (placebo 0%)
dizziness 2.6% (placebo 5.3%)
NCT01096667 · Phase 2 · registry result, not featured evidence
1 mg
musculoskeletal pain 5.1% (placebo 0%)
upper respiratory tract infection 2.6% (placebo 5.3%)
urinary tract infection 2.6% (placebo 2.6%)
NCT01096667 · Phase 2 · registry result, not featured evidence
5 mg
arthralgia 10.9% (placebo 1.9%)
headache 7.3% (placebo 3.7%)
hypoglycaemia 5.5% (placebo 0%)
NCT01059825 · Phase 2 · registry result, not featured evidence
25 mg
genital infection fungal 7.3% (placebo 1.9%)
diarrhoea 5.5% (placebo 1.9%)
upper respiratory tract infection 5.5% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
10 mg
urinary tract infection 9.1% (placebo 7.4%)
genital infection fungal 5.5% (placebo 1.9%)
upper respiratory tract infection 5.5% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
1 mg
arthralgia 3.7% (placebo 1.9%)
diarrhoea 3.7% (placebo 1.9%)
upper respiratory tract infection 3.7% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
15 mg Oral + 100 ug Oral
nasal congestion 12.5%
back pain 0%
headache 0%
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
15 mg Oral + 100 ug IV
headache 25%
back pain 12.5%
nasal congestion 0%
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
15 mg
decreased appetite 12.5%
headache 12.5%
tachycardia 12.5%
NCT02115347 · Phase 1 · registry result, not featured evidence
15 mg
arthralgia 12.5%
back pain 12.5%
dizziness 12.5%
NCT02115347 · Phase 1 · registry result, not featured evidence
4 mg Once Daily
diarrhoea 11.5%
headache 7.7%
abdominal pain 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
2 mg Once Daily
headache 11.5%
constipation 3.8%
dizziness 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
2 mg Twice Daily
abdominal pain 3.8%
diarrhoea 3.8%
dry mouth 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
1 mg Twice Daily
headache 12%
back pain 4%
dyspepsia 4%
NCT01054300 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 6 weeks versus 4 weeks.
  6. fPopulation context differs: baseline_threshold differs (hba1c>=7 versus bmi>=18, hba1c<=10.5, hba1c>=7); comorbidity_diabetes differs (none recorded versus required); prior_therapy differs (unrestricted versus none recorded).
  7. gTreatment context differs: monotherapy versus combination.
  8. hAssessment timepoints differ: 338 weeks versus 312 weeks.
  9. iPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
  10. jThe assessment timepoint is not available for both results.
  11. kTrial phases differ: Phase 4 versus Phase 3.
  12. lPopulation context differs: age eligibility differs (includes children versus adolescents and adults); baseline_threshold differs (hba1c<=11, hba1c>=6.5 versus bmi>=18, hba1c<=10.5, hba1c>=7); comorbidity_cardiovascular_disease differs (none recorded versus required).
  13. mPopulation comparability has not been reviewed for 65 of these studies.
  14. nPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Canagliflozin

Albuminuria Progression 18.3% (n=1298) vs 24% (n=1286) placebo @ 338wk300 mg
responder rate · % of participants
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
20.2% (n=1334) vs 24% (n=1286) placebo @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
UACR Change 24.47 vs 29.3 placebo mg @ 338wk300 mg
absolute change · mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
25.5 vs 29.3 placebo mg @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
33.97 vs 43.41 placebo mg @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7 5 64.9% (n=84) vs 40% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <7.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7 5 69% (n=84) vs 29.3% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <7.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 51.9% (n=84) vs 27.5% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <7%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 54.9% (n=84) vs 22.7% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <7%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 41.6% (n=84) vs 11.3% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <6.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 36.6% (n=84) vs 12% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <6.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
BMI -0.8 vs -0.4 placebo kg @ 26wk100/300 mg
absolute change · kg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
-0.7 vs -0.5 placebo kg @ 52wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
30.53 vs 34.64 placebo kg @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
Body Fat -1.18% (n=60) vs 0.02% (n=50) placebo @ 26wk300 mg
percent change · % of baseline
NCT01106651 · Phase 3 · registry result, not featured evidence
show 2 more results
-1.04% (n=56) vs 0.02% (n=50) placebo @ 26wk100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
32.46% (n=15) vs 38.58% (n=14) placebo @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
Peak VO2 Change mL/Min 0.67 vs -0.53 Sitagliptin kg @ 12wk
absolute change · kg
NCT02920918 · Phase 4 · registry result, not featured evidence
Ventilatory Efficiency Change Slope -0.3 vs -0.3 Sitagliptin Unitless @ 12wk
absolute change · Unitless
NCT02920918 · Phase 4 · registry result, not featured evidence

+ 26 further endpoints in the CSV export.

Ertugliflozin

MACE Plus 4.67 vs 4.92 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
4.42 vs 4.92 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Myocardial Infarction 2 vs 1.7 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
1.55 vs 1.7 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Total MACE 4.91 vs 4.59 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
4.35 vs 4.59 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
CV Death or HF Hospitalization Total 2.71 vs 3.42 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
2.92 vs 3.42 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 8.8% (n=2520) vs 4.7% (n=2727) placebo @ 18wk15 mg
responder rate · % of participants
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 23 more results
10.9% (n=2347) vs 6.1% (n=2311) placebo @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.6% (n=1541) vs 5.8% (n=1496) placebo @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8% (n=1578) vs 5.8% (n=1507) placebo @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.1% (n=860) vs 7.5% (n=786) placebo @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.5% (n=529) vs 6.5% (n=478) placebo @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2% (n=205) vs 2.9% (n=209) placebo @ 26wk15 mg
NCT02033889 · Phase 3
14.6% (n=205) vs 11% (n=209) placebo @ 52wk15 mg
NCT02033889 · Phase 3
12.2% (n=205) vs 7.2% (n=209) placebo @ 104wk15 mg
NCT02033889 · Phase 3
15.4% (n=169) vs 2.4% (n=167) placebo @ 26wk15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
9% (n=2544) vs 4.7% (n=2727) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.4% (n=2363) vs 6.1% (n=2311) placebo @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2% (n=1570) vs 5.8% (n=1496) placebo @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.9% (n=1592) vs 5.8% (n=1507) placebo @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.1% (n=876) vs 7.5% (n=786) placebo @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.3% (n=526) vs 6.5% (n=478) placebo @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.7% (n=207) vs 2.9% (n=209) placebo @ 26wk5 mg
NCT02033889 · Phase 3
10.6% (n=207) vs 11% (n=209) placebo @ 52wk5 mg
NCT02033889 · Phase 3
10.6% (n=207) vs 7.2% (n=209) placebo @ 104wk5 mg
NCT02033889 · Phase 3
14.7% (n=170) vs 2.4% (n=167) placebo @ 26wk5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
20.4% (n=49) vs 6.7% (n=45) placebo @ 12wk5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
14.9% (n=47) vs 6.7% (n=45) placebo @ 12wk25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
13.6% (n=44) vs 6.7% (n=45) placebo @ 12wk10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
12% (n=50) vs 6.7% (n=45) placebo @ 12wk1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
Serum Creatinine Change mg/dL 0.032 vs -0.002 placebo mg/dL @ 18wk15 mg
absolute change · mg/dL
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
0.023 vs 0.004 placebo mg/dL @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.035 vs 0.034 placebo mg/dL @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.035 vs 0.049 placebo mg/dL @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.036 vs 0.059 placebo mg/dL @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.042 vs 0.098 placebo mg/dL @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.001 vs -0.013 placebo mg/dL @ 312wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.022 vs -0.002 placebo mg/dL @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.013 vs 0.004 placebo mg/dL @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.024 vs 0.034 placebo mg/dL @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.037 vs 0.049 placebo mg/dL @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.032 vs 0.059 placebo mg/dL @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.027 vs 0.098 placebo mg/dL @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.034 vs -0.013 placebo mg/dL @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
UACR -14.71% (n=2450) vs 0% (n=2478) placebo @ 18wk15 mg
percent change · % of baseline
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 11 more results
-6.82% (n=2277) vs 5.41% (n=2257) placebo @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.06% (n=2084) vs 17.14% (n=2025) placebo @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.33% (n=1915) vs 27.03% (n=1841) placebo @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
21.25% (n=835) vs 50% (n=745) placebo @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
20% (n=771) vs 48.53% (n=692) placebo @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-13.4% (n=2472) vs 0% (n=2478) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.53% (n=2306) vs 5.41% (n=2257) placebo @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.73% (n=2125) vs 17.14% (n=2025) placebo @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
13.33% (n=1933) vs 27.03% (n=1841) placebo @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
33.33% (n=825) vs 50% (n=745) placebo @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
30.99% (n=780) vs 48.53% (n=692) placebo @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
PPG 2-hr Change mg/dL -3.47 vs 0.27 placebo mmol/L @ 26wk15 mg
absolute change · mmol/L
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -62.45 mg/dL as posted
show 1 more result
-3.56 vs 0.27 placebo mmol/L @ 26wk*5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -64.15 mg/dL as posted
Time to Rescue Therapy 4.57 vs 3.45 placebo months @ 26wk15 mg
time to event · months
NCT02033889 · Phase 3 · converted to months from 139 days as posted
show 1 more result
3.68 vs 3.45 placebo months @ 26wk*5 mg
NCT02033889 · Phase 3 · converted to months from 112 days as posted
Seated SBP -4.82 vs -0.88 placebo mmHg @ 26wk15 mg
absolute change · mmHg
Change from baseline
NCT02036515 · Phase 3
show 3 more results
-4.09 vs 0.83 placebo mmHg @ 52wk15 mg
Change from baseline
NCT02036515 · Phase 3
-3.81 vs -0.88 placebo mmHg @ 26wk5 mg
Change from baseline
NCT02036515 · Phase 3
-4.16 vs 0.83 placebo mmHg @ 52wk5 mg
Change from baseline
NCT02036515 · Phase 3
Seated DBP -1.81 vs -0.43 placebo mmHg @ 26wk15 mg
absolute change · mmHg
Change from baseline
NCT02036515 · Phase 3
show 3 more results
-1.38 vs -0.53 placebo mmHg @ 52wk15 mg
Change from baseline
NCT02036515 · Phase 3
-1.68 vs -0.43 placebo mmHg @ 26wk5 mg
Change from baseline
NCT02036515 · Phase 3
-1.52 vs -0.53 placebo mmHg @ 52wk5 mg
Change from baseline
NCT02036515 · Phase 3
HOMA-B 12.43% (n=151) vs 0.52% (n=147) placebo @ 26wk15 mg
absolute change · percentage points
NCT02036515 · Phase 3
show 3 more results
10.93% (n=152) vs -1.93% (n=152) placebo @ 52wk15 mg
NCT02036515 · Phase 3
13.28% (n=153) vs 0.52% (n=147) placebo @ 26wk5 mg
NCT02036515 · Phase 3
10.85% (n=155) vs -1.93% (n=152) placebo @ 52wk5 mg
NCT02036515 · Phase 3

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · Ertugliflozin's landscape